DekaBank Deutsche Girozentrale bought a new stake in QuidelOrtho Co. (NASDAQ:QDEL – Get Rating) during the 1st quarter, Holdings Channel.com reports. The institutional investor bought 1,838 shares of the company’s stock, valued at approximately $210,000.
Several other large investors have also made changes to their positions in QDEL. Western Pacific Wealth Management LP acquired a new position in QuidelOrtho in the fourth quarter valued at about $26,000. New Century Advisors LLC bought a new position in shares of QuidelOrtho in the fourth quarter valued at approximately $31,000. Exane Derivatives boosted its holdings in shares of QuidelOrtho by 4,883.3% in the 1st quarter. Exane Derivatives now owns 299 shares of the company’s stock worth $34,000 after acquiring an additional 293 shares in the last quarter. Emerald Advisers LLC bought a new stake in QuidelOrtho during the 4th quarter worth approximately $40,000. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new position in QuidelOrtho in the 4th quarter valued at $66,000. Institutional investors own 92.89% of the company’s stock.
QuidelOrtho Stock Performance
Shares of QuidelOrtho stock opened at $103.26 on Monday. QuidelOrtho Co. has a 52 week low of $88.05 and a 52 week high of $180.06. The stock has a market capitalization of $4.32 billion, a price-to-earnings ratio of 4.36 and a beta of 0.04. The firm has a fifty day moving average of $99.72 and a two-hundred day moving average of $103.49.
QuidelOrtho (NASDAQ:QDEL – Get Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported $11.53 EPS for the quarter, beating analysts’ consensus estimates of $9.17 by $2.36. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $865.05 million. QuidelOrtho had a return on equity of 56.46% and a net margin of 43.26%. QuidelOrtho’s revenue was up 167.0% on a year-over-year basis. During the same period in the prior year, the business posted $4.27 EPS. As a group, research analysts forecast that QuidelOrtho Co. will post 14.92 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have recently weighed in on the company. UBS Group initiated coverage on QuidelOrtho in a research note on Wednesday, July 20th. They issued a “sell” rating and a $86.00 target price for the company. JPMorgan Chase & Co. started coverage on QuidelOrtho in a research report on Friday, June 17th. They issued a “neutral” rating on the stock. Finally, StockNews.com raised QuidelOrtho from a “hold” rating to a “buy” rating in a research note on Friday, May 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $98.67.
QuidelOrtho Company Profile
QuidelOrtho Corporation provides various in vitro diagnostics products worldwide. The company’s product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and clinical and at-home products to detect COVID-19. It provides visually-read lateral flow products in infectious disease and reproductive health; direct fluorescent antibodies in infectious disease and virology; micro-titer production with a focus on bone and complement pathway markets; fluorescent immunoassay products; molecular diagnostic products comprising Savanna, an integrated molecular diagnostic system; immunodiagnostics, clinical chemistry, and integrated testing systems to serve diagnostic labs of all sizes; immunodiagnostic donor screening systems and services that drive blood safety; pre-transfusion testing that automates blood bank workload with software to standardize operations, simplify tasks, and improve productivity; and Ortho Care services and informatics products.
Further Reading
Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuidelOrtho Co. (NASDAQ:QDEL – Get Rating).
Receive News & Ratings for QuidelOrtho Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for QuidelOrtho and related companies with MarketBeat.com’s FREE daily email newsletter.
link